Antineoplaston A10

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Antineoplaston A10
Accession Number
DB11702
Type
Small Molecule
Groups
Investigational
Description

Antineoplaston A10 has been used in trials studying the treatment of Sarcoma, Lymphoma, Lung Cancer, Liver Cancer, and Kidney Cancer, among others.

Structure
Thumb
Synonyms
  • Antineoplaston A 10
Categories
UNII
16VY3TM7ZO
CAS number
91531-30-5
Weight
Average: 246.266
Monoisotopic: 246.100442319
Chemical Formula
C13H14N2O3
InChI Key
OQGRFQCUGLKSAV-JTQLQIEISA-N
InChI
InChI=1S/C13H14N2O3/c16-11-7-6-10(13(18)15-11)14-12(17)8-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H,14,17)(H,15,16,18)/t10-/m0/s1
IUPAC Name
N-[(3S)-2,6-dioxopiperidin-3-yl]-2-phenylacetamide
SMILES
O=C(CC1=CC=CC=C1)N[C@H]1CCC(=O)NC1=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
56260
PubChem Substance
347828067
ChemSpider
50771
ChEMBL
CHEMBL1980825

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2TerminatedTreatmentEsophageal Cancers1
2TerminatedTreatmentMesothelioma, Malignant1
2Unknown StatusTreatmentBrain and Central Nervous System Tumors3
2WithdrawnTreatmentAdenocarcinoma of the Colon / Metastatic Colon Cancer / Recurrent Colon Cancer1
2WithdrawnTreatmentAdenocarcinoma of the Prostate / Recurrent Prostate Cancer / Stage III Prostate Cancer / Stage IV Prostate Cancer1
2WithdrawnTreatmentCarcinoma, Islet Cell / Neuroendocrine Carcinoma of the Skin / Neuroendocrine Carcinomas / Pituitary Neoplasms1
2WithdrawnTreatmentContiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Recurrent Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma1
2WithdrawnTreatmentPrimary Central Nervous System Lymphoma (PCNSL)1
2WithdrawnTreatmentRecurrent Breast Cancer / Stage IV Breast Cancer2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.304 mg/mLALOGPS
logP0.37ALOGPS
logP0.13ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)11.56ChemAxon
pKa (Strongest Basic)-2.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.27 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity64.2 m3·mol-1ChemAxon
Polarizability24.89 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-acyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at its terminal nitrogen atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
N-acyl-alpha amino acids and derivatives
Alternative Parents
Phenylacetamides / Piperidinediones / Delta lactams / N-unsubstituted carboxylic acid imides / Dicarboximides / Secondary carboxylic acid amides / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides
show 2 more
Substituents
N-acyl-alpha amino acid or derivatives / Phenylacetamide / Piperidinedione / Delta-lactam / Piperidinone / Monocyclic benzene moiety / Piperidine / Benzenoid / Carboxylic acid imide / Dicarboximide
show 15 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 14:40 / Updated on June 04, 2019 07:26